---
schema_version: "secwatch.filing_event.v1"
accession: "0001559053-22-000017"
form_type: "8-K"
ticker: "PRTA"
cik: "0001559053"
company_name: "PROTHENA CORP PUBLIC LTD CO"
filed_at: "2022-04-26T23:59:59+00:00"
generated_at: "2026-06-26T04:39:38.947027+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Prothena's PRX012 granted FDA Fast Track designation for Alzheimer's treatment

## Summary
- FDA Fast Track designation for PRX012, a next-generation anti-amyloid beta antibody for Alzheimer's.
- PRX012 is currently in Phase 1 clinical study; designed for subcutaneous administration.
- Fast Track may enable more frequent FDA interactions and eligibility for Accelerated Approval and Priority Review.
- Prothena CEO Gene Kinney stated PRX012 has potential to lead a paradigm shift in Alzheimer's treatment.

## SEC filing metadata
- accession: 0001559053-22-000017
- form_type: 8-K
- ticker: PRTA
- cik: 0001559053
- company_name: PROTHENA CORP PUBLIC LTD CO
- filed_at: 2022-04-26T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1559053/000155905322000017/0001559053-22-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1559053/000155905322000017/prta-20220426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001559053-22-000017
- JSON: https://secwatch.observer/filing/0001559053-22-000017.json
- Plain text: https://secwatch.observer/filing/0001559053-22-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.